| Virus-like peptide vaccines against Abeta N-terminal or C-terminal domains reduce amyloid deposition in APP transgenic mice without addition of adjuvant. | |
| | |
MedLine Citation:
|
PMID: 20066498 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Immunotherapy against the Abeta peptide is increasingly viewed as an effective means of preventing and even decreasing Abeta deposition in transgenic mouse models and human cases of Alzheimer's disease. A prior active immunization trial was halted due to adverse events which occurred subsequent to a change in the adjuvant used in the vaccine preparation. Although widely used in experimental studies, adjuvants available for use in vaccines intended for humans are limited. We compared two vaccine preparations in which an immunogenic bacteriophage was conjugated with either an N-terminal (Abeta1-9) or C-terminal (Abeta28-40) peptide sequence from the Abeta molecule. We found that both produced significant antibody titers without use of additional adjuvants. Surprisingly, the response to the N terminal sequence was comprised largely of a stable IgM response, while the C-terminal vaccine produced an IgG response with minimal IgM reactivity. Both of these immunogens reduced Abeta levels when tissues were examined 8 months after the first inoculation. These data demonstrate that (a) C-terminal specific vaccines can effectively lower Abeta and (b) IgM antibodies against Abeta may be capable of lowering Abeta, possibly through action in the brain rather than the periphery. |
| | |
Authors:
|
Qing-you Li; Marcia N Gordon; Bryce Chackerian; Jennifer Alamed; Kenneth E Ugen; Dave Morgan |
Related Documents
:
|
22251998 - Benefits to mother and child of influenza vaccination during pregnancy. 18072728 - Structure-activity relationship of a series of synthetic lipopeptide self-adjuvanting g... 21749758 - Invasive group a streptococcal infection and vaccine implications, auckland, new zealand. 3527818 - Role of muramyl peptides for the enhancement of synthetic vaccines. 20724968 - National, state, and local area vaccination coverage among adolescents aged 13-17 years... 17265398 - Influenza vaccination rates and motivators among healthcare worker groups. |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology Volume: 5 ISSN: 1557-1904 ISO Abbreviation: J Neuroimmune Pharmacol Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-03-02 Completed Date: 2010-05-11 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101256586 Medline TA: J Neuroimmune Pharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 133-42 Citation Subset: IM |
Affiliation:
|
Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, FL, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Alzheimer Disease
/
drug therapy*,
immunology,
metabolism,
pathology,
prevention & control Amyloid beta-Protein / chemistry, immunology, metabolism Amyloid beta-Protein Precursor / genetics* Animals Brain / immunology, metabolism, pathology Disease Models, Animal Drug Carriers / chemical synthesis, therapeutic use Immunoglobulin G / blood Immunoglobulin M / blood Mice Mice, Transgenic Vaccination / methods Vaccines, Subunit / administration & dosage, chemical synthesis* Virion / chemistry, immunology* |
| Grant Support | |
ID/Acronym/Agency:
|
AG15490/AG/NIA NIH HHS; AG18478/AG/NIA NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Amyloid beta-Protein; 0/Amyloid beta-Protein Precursor; 0/Drug Carriers; 0/Immunoglobulin G; 0/Immunoglobulin M; 0/Vaccines, Subunit |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Chemotherapy resistance research of lung cancer based on micro-fluidic chip system with flow medium.
Next Document: Mechanisms of bolus clearance in patients with laparoscopic adjustable gastric bands.